Spinocerebellar Ataxia (SCA) - Pipeline Review, H1 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jun 5, 2018--The “Spinocerebellar Ataxia (SCA) - Pipeline Review, H1 2018” report has been added to ResearchAndMarkets.com’s offering.
Spinocerebellar Ataxia (SCA) - Pipeline Review, H1 2018, provides an overview of the Spinocerebellar Ataxia (SCA) (Genetic Disorders) pipeline landscape.
This latest pipeline guide Spinocerebellar Ataxia (SCA) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Spinocerebellar Ataxia (SCA) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Spinocerebellar Ataxia (SCA) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Spinocerebellar Ataxia (SCA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 1, 4 and 2 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 1 and 2 molecules, respectively.
Spinocerebellar Ataxia (SCA) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:Introduction Report Coverage Spinocerebellar Ataxia (SCA) - Overview Spinocerebellar Ataxia (SCA) - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Spinocerebellar Ataxia (SCA) - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Spinocerebellar Ataxia (SCA) - Companies Involved in Therapeutics Development Bio Blast Pharma Ltd Biohaven Pharmaceutical Holding Company Ltd Cadent Therapeutics Ionis Pharmaceuticals Inc Shionogi & Co Ltd Spark Therapeutics Inc Vybion Inc WAVE Life Sciences Ltd
For more information about this report visit https://www.researchandmarkets.com/research/c99plk/spinocerebellar?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180605006719/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Central Nervous System Drugs
INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS GENETICS PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 06/05/2018 04:54 PM/DISC: 06/05/2018 04:54 PM